Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

Purpose: To evaluate carrier-mediated intestinal secretion of talinolol enantiomers in vivo and in vitro.

Methods: In clinical studies with i.v.

Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans.

Twelve healthy subjects were investigated on six separate occasions at least 1 week apart when they either received a single oral dose of 80 mg propranolol; 25, 50, 100, or 400 mg talinolol; or placebo (double-blinded, period-balanced six-way cross-over design). The subjects were investigated during supine rest and performed supine bicycle ergometry 0200, 0500, 0730, 1000, and 2400 h after dosing. Isoprenaline (ISO) and epinephrine (EPI) were infused intravenously (i.

Quality of cefotaxime sodium preparations.

Cefotaxime sodium (CAS 64485-93-4) is a semisynthetic cephalosporin derivative belonging to the third-generation cephalosporins. Owing to its broad antibacterial activity and its high resistance to beta-lactamases it can be used for a large variety of infections. In the present study the quality standard of 15 different cefotaxime sodium manufacturers from 9 different countries has been examined.